View in EDS HTML Full Text PDF Full Text

CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.

Saved in:
Bibliographic Details
Title: CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.
Authors: Qin X; School of Medicine, Nankai University, Tianjin, China.; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China., Chang Y; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China., Qiu Y; School of Life Sciences, Biomedical Pioneering Innovation Center, Peking University, Beijing, China., Han W; School of Medicine, Nankai University, Tianjin, China. hanwdrsw@163.com.; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. hanwdrsw@163.com., Nie J; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. nnjj2002@163.com.
Source: NPJ breast cancer [NPJ Breast Cancer] 2026 Jan 24; Vol. 12 (1). Date of Electronic Publication: 2026 Jan 24.
Publication Type: Journal Article
Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41580422
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Qin+X%22">Qin X</searchLink>; School of Medicine, Nankai University, Tianjin, China.; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Chang+Y%22">Chang Y</searchLink>; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Qiu+Y%22">Qiu Y</searchLink>; School of Life Sciences, Biomedical Pioneering Innovation Center, Peking University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Han+W%22">Han W</searchLink>; School of Medicine, Nankai University, Tianjin, China. hanwdrsw@163.com.; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. hanwdrsw@163.com.<br /><searchLink fieldCode="AU" term="%22Nie+J%22">Nie J</searchLink>; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. nnjj2002@163.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101674891%22">NPJ breast cancer</searchLink> [NPJ Breast Cancer] 2026 Jan 24; Vol. 12 (1). <i>Date of Electronic Publication: </i>2026 Jan 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Breast+Cancer+Research+Foundation%22">Breast Cancer Research Foundation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101674891 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2374-4677 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223744677%22">23744677 </searchLink><i>NLM ISO Abbreviation: </i>NPJ Breast Cancer <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41580422
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41523-026-00895-3
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Qin X
      – PersonEntity:
          Name:
            NameFull: Chang Y
      – PersonEntity:
          Name:
            NameFull: Qiu Y
      – PersonEntity:
          Name:
            NameFull: Han W
      – PersonEntity:
          Name:
            NameFull: Nie J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 01
              Text: 2026 Jan 24
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2374-4677
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: NPJ breast cancer
              Type: main
ResultId 1